GSK, the WHO and a Malaria Vaccine

Dr Vernon Coleman

Is this ever going to end?

The World Health Organisation has recommended that a malaria vaccine developed by GlaxoSmithKline should be widely used in children in Africa and other parts of the world. The drug, was created in 1987, and in October 2019 a paper in ‘Human Vaccines and Immunotherapeutics’ reported that the first generation vaccine demonstrated ‘modest efficacy against malaria illness’.

According to the Financial Times, the drug, called Mosquirix, is being used in experimental pilot studies and more than 800,000 children in Ghana, Kenya and Malawi have been given it. That’s some test.

According to the WHO around 2.3 million doses have so far been given.

So, let’s get this straight.

They’ve vaccinated 2.3 million children in Africa and elsewhere with this malaria vaccine. And now, after giving it to 2.3 million children, the WHO has recommended that it be widely used in sub Saharan Africa and other regions at risk.

Back in November 2019, a headline in the journal ‘Science’ read: ‘First malaria vaccine rolled out in Africa – despite limited efficacy and nagging safety concerns’.

So what are these safety concerns?

Well, according to the report in ‘Science’ children who received Mosquirix had a risk of meningitis ten times higher than those who received a control vaccine. (I don’t know what the control vaccine was.) And then the WHO decided to give the vaccine to hundreds of thousands of children to see what happened.

According to the European Medicines Agency the most severe side effect reported with Mosquirix was febrile seizures (fits with a fever) which occurred in 1 child in 1,000. The most common side effects were fever, which affected about 1 child in four, irritability, pain and swelling.

For completeness, let me remind you about GlaxoSmithKline, known to its enemies as GSK.

The following is taken from my free book ‘Covid 19 Exposing the Lies’ which is available from and

‘GSK is one of the world’s biggest pharmaceutical companies. It is one of the top earning vaccine companies in the world. Take a look at its track record.

In 2006, GSK paid out $160 million for claims made by patients who had become addicts. In 2009, GSK paid out $2.5 million to the family of a three-year-old born with severe heart malformations. And in Canada, a five-year-old girl died five days after an H1N1 flu shot, and her parents sued GSK for $4.2 million. The parents’ lawyer alleged that the drug was brought out quickly and without proper testing as the federal government exerted intense pressure on Canadians to get immunised.

In 2010, GSK paid out $1.14 billion because of claims over a drug called Paxil. And they settled lawsuits over a drug called Avandia for $500 million.

In 2011, GSK paid $250 million to settle 5,500 death and injury claims and set aside $6.4 billion for future lawsuits and settlements in respect of the drug Avandia.

In 2012, GSK pleaded guilty to federal criminal offences including misbranding of two antidepressants and failure to report safety data about a drug for diabetes to the FDA in America. The company admitted to illegally promoting Paxil for the treatment of depression in children and agreed to pay a fine of $3 billion. That was the largest health care fraud settlement in US history. GSK also reached a related civil settlement with the US Justice Department. The $3 billion fine also included the civil penalties for improper marketing of half a dozen other drugs.

In 2014, GSK was fined $490 million dollars by China after a Chinese court found it guilty of bribery. The court gave GSK’s former head of Chinese operations a suspended prison sentence and gave suspended prison sentences to other executives too.

In 2016, GSK paid out $6.2 million in Canada.

In 2017, GSK were ordered to pay $3 million to a widow.

In 2018, GSK faced 445 lawsuits over a drug called Zofran.

There are a couple of other things you should know about GSK.

First, in 2010, there were reports of narcolepsy occurring in Sweden and Finland among children who had the H1N1 swine flu vaccine. It is reported that not all the safety problems were made public. I have seen a report that by December 2009, for each one million doses of the vaccine given, about 76 cases of serious adverse events were reported though this was not made public. A paper published in the British Medical Journal in 2018, reported that GSK had commented that ‘further research is needed to confirm what role Pandemrix may have played in the development of narcolepsy among those involved.’

The writer of the BMJ article commented: ‘Now, eight years after the outbreak, new information is emerging from one of the lawsuits that, months before the narcolepsy cases were reported, the manufacturer and public health officials were aware of other serious adverse events logged in relation to Pandemrix.’

Second, Sir Patrick Vallance is the Chief Scientific Adviser in the United Kingdom. Vallance worked for GSK between 2006 and 2018. By the time he left GSK, he was a member of the board and the corporate executive team. The fines and so on which I have listed took place while Vallance was working as a senior figure at GSK. The last time I looked Vallance still held a big chunk of shares in GSK.

In my opinion, both GSK and the WHO should be closed down.

But I can pretty well guarantee that neither of those things are going to happen.

On the other hand I can equally guarantee that my videos and websites will continue to be suppressed and I will continue to be vilified and attacked as a conspiracy theorist.

Copyright Vernon Coleman October 2021